drugset / Trial / NCT07022418

Formoterol in Diabetes

NCT07022418

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of not receiving formoterol fumarate. Both groups will continue their standard of care treatment during the study. The primary goal is to gather data on feasibility and effect sizes to properly power a future clinical trial.

Timeline

Start
2025-12-01
Primary completion
2026-12
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 20 ug Inhaled